Endo International plc
Glandore Business Centres
No. 33 Fitzwilliam Square
Dublin 2
Tel: 353-1-669-8559 or 800-462-3636
Fax: 800-329-3636
Website: http://www.endo.com/
312 articles about Endo International plc
-
Endo to Announce Third-Quarter 2018 Financial Results
9/28/2018
Endo International plc (NASDAQ: ENDP) will announce its third-quarter 2018 financial results on November 8, 2018 and members of its senior management team will host a conference call and webcast at 8:00 a.m. ET before the U.S. financial markets open.
-
Endo Pharmaceuticals Issues Voluntary Nationwide Recall for Two Lots of Robaxin® 750mg Tablets 100 Count Bottle Packs Due to Incorrect Daily Dosing Information on Label
9/28/2018
Endo International plc today announced that one of its operating companies, Endo Pharmaceuticals Inc., is voluntarily recalling two lots of Robaxin® (methocarbamol tablets, USP) 750mg Tablets 100 Count Bottle pack to the consumer level.
-
Endo Agrees to Additional Stay of FDA Litigation Following FDA's Commitment to Use Best Efforts to Finalize Vasopressin Clinical Need Determination By Year End
9/24/2018
Endo International plc today announced that it has agreed to an additional stay of its litigation against the U.S. Food and Drug Administration (FDA) until December 31, 2018.
-
In a 99 to 1 vote, the Senate passed the bill that looks to cut down on the flow of illegal narcotics entering the United States through the mail, as well as taking aim at the abuse of prescription opioid medication – a problem that has grown to an epidemic in the United States.
-
Endo to Participate at Morgan Stanley Global Healthcare Conference
9/6/2018
Endo International plc (NASDAQ: ENDP) announced today that members of management will participate in a fireside chat at the Morgan Stanley 16th Annual Global Healthcare Conference in New York City on Wednesday, September 12, 2018 at 9:55 a.m. ET.
-
President Donald Trump has called on U.S. Attorney General Jeff Sessions to file lawsuits against certain drug manufacturers whose drugs have contributed to the opioid crisis.
-
Endo Lifts Temporary Stay of FDA Litigation Following the Launch of a Bulk-Compounded Vasopressin Product by a Section 503B Outsourcing Facility
8/15/2018
The litigation also seeks the immediate removal of vasopressin from FDA's Category 1 nominations list to assure that outsourcing facilities do not engage in bulk compounding of vasopressin-containing drug products under Section 503B.
-
Endo Reports Second-Quarter 2018 Financial Results
8/8/2018
Second-quarter 2018 revenues of $715 million compared to second-quarter 2017 revenues of $876 million
-
Allergan is suing Pfizer over morphine-based opioid drugs, Kadian, that Allergan acquired in December 2008. Read more if you wish to know more about this matter.
-
Endo Announces Appointment of Laure Park as Senior Vice President, Investor Relations and Corporate Affairs
8/2/2018
Laura will serve as a member of Endo's executive leadership team
-
Endo Begins Shipment of Authorized Generic Version of INVANZ® (ertapenem for injection) in the United States
7/27/2018
Endo International plc announced today that one of its operating companies, Par Pharmaceutical (Par), has begun shipping an authorized generic version of Merck's INVANZ® (ertapenem for injection)
-
Bioprojet and Endo Jointly Announce Agreement for Paladin Labs Inc. to Commercialize Pitolisant in Canada
7/25/2018
Agreement to register, commercialize, and distribute pitolisant on an exclusive basis in Canada.
-
Endo to Announce Second-Quarter 2018 Financial Results
7/20/2018
Endo International plc will announce its second-quarter 2018 financial results on August 8, 2018
-
Endo Begins Shipment of Authorized Generic Version of Colcrys® (colchicine, USP) in the United States
7/2/2018
Endo International plc announced that one of its operating companies, Par Pharmaceutical, Inc. (Par), has begun shipping an authorized generic version of Takeda Pharmaceutical's Colcrys® (colchicine, USP) 0.6 mg tablets.
-
Endo Announces Master Settlement Agreement Allowing for Resolution of Known Testosterone Replacement Therapy Product Liability Claims and Entry of Significant Case Management Order
6/11/2018
Endo International plc announced that its subsidiaries Endo Pharmaceuticals Inc. and Auxilium Pharmaceuticals, LLC have executed a definitive master settlement agreement allowing for the resolution of all known testosterone replacement therapy product liability claims against the Company.
-
Orchard Therapeutics Announces Appointments of Marc Dunoyer and Charlie Rowland to Board of Directors
6/7/2018
Orchard Therapeutics today announced the appointments of Marc Dunoyer and Charlie Rowland to its board of directors as independent directors.
-
Indivior Enters into Settlement with Par Pharmaceutical in Patent Infringement Case
5/14/2018
Indivior PLC today announced that its U.S. subsidiary, Indivior Inc., together with Aquestive Therapeutics Inc., entered into a settlement agreement with Par Pharmaceutical, Inc., Par Pharmaceutical Companies Inc., Endo International PLC and IntelGenx Technologies Corp., resolving patent litigation related to SUBOXONE® Sublingual Film.
-
Endo to Participate at the UBS Global Healthcare Conference
5/2/2018
Endo International plc announced that Paul Campanelli, President and CEO, will participate in a fireside chat at the UBS Global Healthcare Conference in New York City on Monday, May 21, 2018 at 11:00 a.m. ET.
-
Collagenase Clostridium Histolyticum For The Investigational Treatment Of Cellulite To Be Featured During The Hot Topics Symposium At The Aesthetic Meeting 2018
4/27/2018
Endo International plc announced the presentation of clinical data from a Phase 2b investigational study of collagenase clostridium histolyticum (CCH) for the treatment of cellulite.
-
Endo to Acquire Somerset Therapeutics and Business of Affiliate Wintac Limited
4/26/2018
Endo International plc (NASDAQ: ENDP) today announced that it has reached definitive agreements to acquire Somerset Therapeutics, LLC, a New Jersey based specialty pharmaceutical company that develops and markets sterile injectable and ophthalmic drugs for the U.S. marketplace, and the business of its India based affiliate Wintac Limited, which operates as Somerset Therapeutics' contract developer and manufacturer